Your session is about to expire
← Back to Search
HyperSight Imaging for Pelvic Cancer
N/A
Recruiting
Research Sponsored by Varian, a Siemens Healthineers Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1-9 weeks
Awards & highlights
Study Summary
This trial will evaluate the integration of a new imaging system to help align patients with their radiation treatment. Images will be compared for quality & utility vs. existing images. No aspect of patient treatment affected.
Who is the study for?
This trial is for adults who are set to receive radiation therapy for cancers in the head, neck, thorax, abdomen, or pelvis. They must have good kidney function if receiving IV contrast and women of childbearing age need a negative pregnancy test. It's not open to those unable to consent or considered vulnerable.Check my eligibility
What is being tested?
The study tests HyperSight imaging integrated with the TrueBeam radiotherapy system by Varian Medical Systems. The goal is to see if this new CBCT imaging can provide clearer images than conventional methods without affecting patients' ongoing radiation treatments.See study design
What are the potential side effects?
Since HyperSight/TrueBeam is used only for imaging and doesn't affect treatment delivery, there are no additional side effects expected from participating in this study beyond those associated with standard radiation therapy.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1-9 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1-9 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Feasibility of using HyperSight CBCT images for radiation treatment planning.
Other outcome measures
Confidence in image registration
Feasibility of obtaining respiratory gated HyperSight CBCT
Image quality - qualitative
+8 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: HyperSight Imaging armExperimental Treatment1 Intervention
Subjects are imaged with the new HyperSight CBCT imaging system.
Find a Location
Who is running the clinical trial?
Varian, a Siemens Healthineers CompanyLead Sponsor
30 Previous Clinical Trials
7,233 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My kidneys work well enough for IV contrast, with an eGFR over 30.I can join the study without a kidney test if I'm not getting IV contrast.I am not in a position to fully understand or decide about participating in this study without influence.I am scheduled for radiation therapy on my head, neck, chest, abdomen, or pelvis.I am 18 years old or older.
Research Study Groups:
This trial has the following groups:- Group 1: HyperSight Imaging arm
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any unfilled opportunities for participants in this research endeavor?
"It appears that this trial is not presently accepting any more participants. According to records on clinicaltrials.gov, the study had been posted since August 1st of 2023 and was last updated on the 9th; however, there are still 347 other trials recruiting patients at present."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger